Start Date
Immediate
Expiry Date
11 Sep, 25
Salary
0.0
Posted On
13 Jun, 25
Experience
0 year(s) or above
Remote Job
Yes
Telecommute
Yes
Sponsor Visa
No
Skills
Good communication skills
Industry
Hospital/Health Care
Company Description
The Myriad Women’s Health Regional Medical Specialist (MWH RMS) is a strategic and critical position within the company, responsible for providing clinical education and support on prenatal genetics and hereditary cancer risk assessment and management, to healthcare providers and key opinion leaders. The MWH RMS supports three products: Myriad myRisk® hereditary cancer panel (including riskScore®), Myriad Prequel™ NIPS screen and Myriad Foresight® carrier screening panel.
Job Description
Location: United States
Job Identification: 2485
Job Schedule: Full time
Bioinformatics Analyst I - SLC/WFH
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all, empowering individuals with vital genetic insights and enabling healthcare providers to better detect, treat and prevent disease. Myriad discovers and commercializes genetic tests that determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across medical specialties where critical genetic insights can significantly improve patient care and lower healthcare costs. Here are some of the things that make Myriad a life changer:
This bioinformatics analyst position supports the myChoice CDx and related products. myChoice CDx is the most comprehensive tumor test that determines HRD status in patients with ovarian cancer. This FDA-approved test helps provide information on the magnitude of benefit for PARP inhibitor therapy. This position will assist various groups in interpreting the failed, inconclusive, or complicated results that are output by the myChoice CDx assay, as well as assisting with FDA required analyzes. In addition to myChoice CDx, this position will assist in the development of new myChoice products as well as related R&D endeavors.